Related Experiment Videos
Zidovudine (Retrovir) update.
1Department of Medicine, Sunnybrook Health Science Centre, Toronto, Ont.
Summary
Zidovudine (AZT) can safely delay HIV progression and prolong survival, especially at lower doses with fewer toxic effects. Optimal timing for initiating AZT in early HIV infection requires further research.
Area of Science:
- Virology
- Immunology
- Pharmacology
Background:
- Zidovudine (AZT) was the first licensed antiretroviral for HIV infection.
- Its efficacy has been studied across various stages of HIV disease.
Purpose of the Study:
- To comprehensively analyze the clinical efficacy and adverse effects of zidovudine in different HIV infection stages.
- To review current data for physicians treating HIV-infected patients.
Main Methods:
- MEDLINE search for articles published since 1985.
- Evaluation of controlled studies, long-term therapy, HIV-related conditions, and adverse reactions.
- Review of international meeting abstracts.
Main Results:
- No significant difference in clinical outcome between high-dose and low-dose AZT.
- Significantly fewer toxic effects observed with low-dose AZT.
- AZT delayed disease progression in asymptomatic/mildly symptomatic HIV patients with CD4 < 0.5 x 10(9)/L.
Conclusions:
- AZT can be safely used to delay AIDS progression and prolong survival in certain HIV patients.
- Further research is needed to determine optimal treatment initiation and manage toxicity.
- Combination therapy and prophylaxis strategies require additional investigation.